Zobrazeno 1 - 10
of 4 828
pro vyhledávání: ''
Autor:
Oscar B. Lahoud, Heather Landau, James Nguyen, Sean Devlin, Nikoletta Lendvai, Jonathan Weltz, Tumininu Ayorinde, David J. Chung, Alexander M. Lesokhin, Tarun Kewalramani, Neha Korde, Sham Mailankody, Ola Landgren, Sergio Giralt, Raymond L. Comenzo, Hani Hassoun
Publikováno v:
Leukemialymphoma. 63(9)
Although upfront autologous stem cell transplantation (ASCT) generally improves progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), the overall survival (OS) benefit and optimal timing of ASCT are not well established. Patient
Autor:
Morie Gertz
Publikováno v:
Leukemialymphoma. 63(9)
Smoldering multiple myeloma has been recognized for over 40 years and represents a pre-symptomatic phase of the 2nd most common hematologic malignancy. 1/3 of patients will remain asymptomatic at 10 years. There is an identifiable subset of patients
Autor:
Alyce M. Kuo, Hani Hassoun, Urvi Shah, Allison Gordon, Travis J. Hollmann, Heather J. Landau, Cecilia Lezcano, Sham Mailankody, Carlyn C. Tan, Alexander M. Lesokhin, Alina Markova
Publikováno v:
Leukemialymphoma. 63(9)
Autor:
Evan C. Chen, Yiwen Liu, Courtney E. Harris, Eric S. Winer, Martha Wadleigh, Andrew A. Lane, Rahul S. Vedula, R. Coleman Lindsley, Kevin M. Copson, Anne Charles, Francisco Marty, Donna Neuberg, Daniel J. DeAngelo, Richard M. Stone, Marlise R. Luskin, Nicolas C. Issa, Jacqueline S. Garcia
Publikováno v:
Leukemialymphoma. 63(8)
Antifungal prophylaxis (AFP) is recommended for acute myeloid leukemia (AML) patients receiving the combination of venetoclax (VEN) and a hypomethylating agent (HMA), but the benefit of this practice is unclear. We identified 131 patients with newly
Autor:
Rena Buckstein, Lisa Chodirker, Karen W.L. Yee, Michelle Geddes, Heather A. Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
Publikováno v:
Leukemialymphoma.
Many patients with lower-risk myelodysplastic syndromes (LR MDS) require long-term red blood cell (RBC) transfusions to manage anemia. The consequences of RBC transfusions in LR MDS with ring sideroblasts (LR MDS-RS) are not well known. We estimated
Autor:
Clara Sortais, Stéphanie Cordeil, Estelle Bourbon, Maryam Idlhaj, Emmanuelle Ferrant, Violaine Safar, Camille Golfier, Anne Lazareth, Fadhela Bouafia-Sauvy, Jérémie Tordo, Hervé Ghesquières, Pierre Sesques, Emmanuel Bachy
Publikováno v:
Leukemialymphoma.
Autor:
Alexandre Butelet, Stéphanie Poulain, Emmanuelle Jeanpierre, Micha Srour, Morgane Nudel, Paul Chauvet, Anne Bauters, Sophie Susen, Annabelle Dupont, Marie de Charette
Publikováno v:
Leukemialymphoma. 63(13)
Ibrutinib, a first-class Bruton tyrosine kinase inhibitor, is known to be associated with adverse bleeding events and has been recently approved for the treatment of relapse Waldenström macroglobulinemia (WM). Here, we report the exhaustive clinical
Autor:
Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba
Publikováno v:
Leukemialymphoma.
Autor:
Alexander Coltoff
Publikováno v:
Leukemialymphoma.
The Philadelphia-negative myeloproliferative neoplasms (MPNs)-essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF), are characterized by a propensity for thrombotic events and variable risks for transformation to MF (for ET a
Autor:
Kurt S. Bantilan, Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Jose F. Leis, Wei Ding, Susan L. Slager, Jacob D. Soumerai, Lindsey E. Roeker, Anthony Mato, Andrew D. Zelenetz
Publikováno v:
Leukemialymphoma.
Targeted therapies have largely replaced chemoimmunotherapy (CIT) in first-line treatment of chronic lymphocytic leukemia (CLL). We aimed to develop a prognostic model to determine who would benefit from first-line CIT vs target therapy. In follicula